Open AccessA Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Author(s) -
Srđan Verstovšek,
Ruben A. Mesa,
Jason Gotlib,
Richard S. Levy,
Vikas Gupta,
John F. DiPersio,
John Catalano,
Michael W. Deininger,
Carole B. Miller,
Richard T. Silver,
Moshe Talpaz,
Elliott F. Winton,
Jimmie H. Harvey,
Murat O. Arcasoy,
Elizabeth O. Hexner,
Roger M. Lyons,
Ronald Paquette,
Azra Raza,
Kris Vaddi,
Susan EricksonViitanen,
Iphigenia L. Koumenis,
William Sun,
Victor Sandor,
Hagop M. Kantarjian
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1110557
Subject(s) - ruxolitinib , myelofibrosis , janus kinase inhibitor , placebo , medicine , janus kinase , clinical trial , janus kinase 2 , double blind , oncology , pathology , alternative medicine , bone marrow , receptor
Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom